A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs GSK 189254 (Primary) ; Duloxetine
- Indications Hyperalgesia
- Focus Pharmacodynamics
- 17 Aug 2007 Status changed from recruiting to completed.
- 03 Dec 2006 New trial record.